Noema Pharma, Founded by Sofinnova Partners, Raises CHF 103 Million (USD 112 Million) in Series B Financing
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx. USD 112 million) Series B financing round. Sofinnova co-founded and seed financed Noema in 2019 with Dr. George Garibaldi and Luigi Costa. The company was established to advance clinical stage assets in-licensed from Roche.
Noema is a clinical-stage biopharmaceutical company focused on central nervous system disorders. Existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus welcomed new investors Forbion and Jeito Capital, as well as UPMC Enterprises and another undisclosed investor.
The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets, including its lead compound basimglurant (NOE-101), an mGluR5 inhibitor that is being evaluated in Phase 2b clinical trials for severe pain in Trigeminal Neuralgia (TN) and seizures in Tuberous Sclerosis Complex (TSC). The company is also developing gemlopodect (NOE-105), a PDE10a inhibitor being evaluated in Phase 2b clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder (COFD) or Stuttering; and NOE-115, a Phase 2 ready triple reuptake inhibitor for Atypical Depression and Binge Eating Disorder.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “As co-founders and initial investors of Noema, we are incredibly proud of what the company has accomplished since its inception. Raising an oversubscribed funding round of this magnitude is a significant achievement that further reinforces our conviction that Noema can make a meaningful difference in the lives of patients suffering from debilitating CNS disorders . Noema is the perfect illustration of our core strategy and expertise: we nurture innovative companies centered on groundbreaking science and exceptional talent that have the potential to deliver transformative results for patients.”
Luigi Costa, Chief Executive Officer of Noema Pharma, said: "We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”
The Series B financing follows a CHF 54 million (approx. USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners. Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
About Noema Pharma
Noema Pharma (www.noemapharma.com) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005296/en/
Contact information
Bommy Lee
Head of Communications
Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)14.5.2025 09:14:00 EEST | Press release
GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 billion upfront, with potential for additional success-based milestone payments totalling $800 million. Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), including cirrhosis, and future development in alcohol-related liver disease (ALD), both forms of SLD. Given efimosfermin’s direct antifibrotic mechanism of action and GSK’s dat
Reply Presents “App to the Future”: A New AI-Scape Room Experience Powered by Microsoft AI and Low-Code Solutions14.5.2025 09:05:00 EEST | Press release
Reply, a global systems integrator and technology consulting firm, introduces “App to the Future” an immersive “AI-Scape Room” an immersive escape room experience powered by Microsoft Copilot, Azure AI, and Power Platform, designed to explore the full potential of AI and low-code tools in a unique and engaging way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513072546/en/ The experience builds on Reply’s AI-Scape Room focused on Microsoft 365 Copilot, offering enhanced challenges and deeper integration of advanced AI tools to help participants better understand how these technologies can drive business transformation. Developed by WM Reply and Valorem Reply, the Reply companies specialised in digital workplace transformation and AI solutions, “App to the Future” invites participants to engage in an interactive experience where they tackle AI-powered challenges using Microsoft’s suite of tools - including Copilot, Azure
Svante Launches World's First Commercial Gigafactory for Carbon Capture & Removal Filters13.5.2025 23:50:00 EEST | Press release
Svante Technologies Inc. (Svante), a global leader in carbon capture and removal technologies, has officially completed the commissioning of its new Centre of Excellence for Carbon Capture and Removal – Redwood manufacturing Facility (Redwood) in Burnaby, British Columbia. This milestone marks the launch of the world's first gigafactory dedicated to producing commercial-scale carbon capture and removal filters designed to trap CO2 directly from industrial emissions and the atmosphere, and with the mindset of high-volume automation and product standardization to lower the manufacturing cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513713072/en/ Claude Letourneau, President & CEO, Svante Group opens the Svante Grand Opening 2025 event, "GO25" with a speech about how to move the carbon management industry forward. This two-day event celebrates the commissioning of Svante's gigafactory in Vancouver, BC, Canada, which w
Svante and SAMSUNG E&A Sign Joint Development Agreement to Offer Digitally Enabled Skid-Mounted Modular Carbon Capture Plants13.5.2025 23:46:00 EEST | Press release
Svante Technologies Inc. (Svante) and SAMSUNG E&A announced today that they have signed a joint development agreement to jointly develop a set of standardized skid-mounted modular carbon capture plants based on Svante’s novel VeloxoTherm solid sorbent-based carbon capture filter technology, leveraging SAMSUNG E&A’s advanced digital solutions and modularization capabilities. The agreement was signed during Svante’s Grand Opening Event, which marked the commissioning of its new commercial filter manufacturing facility in Vancouver, Canada. This is the world’s first gigafactory for Svante’s filter technology, capable of producing enough filters to capture 10 million tonnes of CO2 annually. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513282760/en/ Leaders of SAMSUNG E&A and Svante sign a joint development agreement at a private signing ceremony during Svante's Grand Opening Event in Burnaby, BC, Canada. The companies have
AWS and HUMAIN Announce Groundbreaking AI Zone to Accelerate AI Adoption in Saudi Arabia and Globally13.5.2025 19:09:00 EEST | Press release
Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and HUMAIN, Saudi Arabia’s newly created company responsible for driving AI innovation across the Kingdom and globally, today announced plans to invest $5 billion-plus in a strategic partnership to build a groundbreaking “AI Zone” in the Kingdom. This first-of-a-kind AI Zone will bring together multiple innovative capabilities, including dedicated AWS AI infrastructure and servers with world-class semiconductors, UltraCluster networks for faster AI training and inference, AWS services like SageMaker and Bedrock, and AI application services such as Amazon Q to advance Saudi Arabia’s mission to be a world leader in AI. AWS previously announced and is currently building an AWS infrastructure region in Saudi Arabia that will become available in 2026. Amazon is investing US$5.3 billion (approx. 19.88 billion Saudi riyal) in Saudi Arabia to develop this new region for AWS. The new AI Zone announced today is an addit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom